Dazukibart

DB18429InvestigationalProtein Based Therapies

Dazukibart: Overview.

Mechanism
Curator reviewed
Also known as
Immunoglobulin G1 [236-alanine,237-alanine,239-alanine,de-C-terminal-lysine], anti-(human interferon β) (human-Mus musculus monoclonal PF-06823859 γ1-chain), disulfide with human-Mus musculus monoclonal PF-06823859 κ-chain, dimer · Mab humanized (igg1) anti p01574 (ifnb_human) (pf06823859) · Recombinant humanized monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1kappa) directed against human soluble cytokine interferon beta.
Code names
PF-06823859

Resolves to

Compound
UNIIK2Q0JXS9B4CAS2639474-65-8
Targets
P01574IFNB1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Dazukibart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In